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Abstract  
We describe a new method to automatically discriminate between patients with Alzheimer’s disease 
(AD) or mild cognitive impairment (MCI) and elderly controls, based on multidimensional 
classification of hippocampal shape features. This approach uses spherical harmonics (SPHARM) 
coefficients to model the shape of the hippocampi, which are segmented from magnetic resonance 
images (MRI) using a fully automatic method that we previously developed. SPHARM coefficients 
are used as features in a classification procedure based on support vector machines (SVM). The 
most relevant features for classification are selected using a bagging strategy. We evaluate the 
accuracy of our method in a group of 23 patients with AD (10 males, 13 females, age ± standard-
deviation (SD) = 73 ± 6 years, mini-mental score (MMS) = 24.4 ± 2.8), 23 patients with amnestic 
MCI (10 males, 13 females, age ± SD = 74 ± 8 years, MMS = 27.3 ± 1.4) and 25 elderly healthy 
controls (13 males, 12 females, age ± SD = 64 ± 8 years), using leave-one-out cross-validation. For 
AD vs controls, we obtain a correct classification rate of 94%, a sensitivity of 96%, and a 
specificity of 92%. For MCI vs controls, we obtain a classification rate of 83%, a sensitivity of 
83%, and a specificity of 84%. This accuracy is superior to that of hippocampal volumetry and is 
comparable to recently published SVM-based whole-brain classification methods, which relied on a 
different strategy. This new method may become a useful tool to assist in the diagnosis of 
Alzheimer’s disease. 
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Introduction 
Alzheimer’s disease (AD) is the most prevalent form of dementia in the elderly and the number of 
affected patients is expected to double in the next 20 years (Ferri et al., 2005). Accurate diagnosis of 
AD can be challenging, in particular at the earlier stage. Early diagnosis of AD patients is important 
because it allows early treatment with cholinesterase inhibitors, which have been shown to delay 
institutionalization, improve or stabilize cognition and behavioral symptoms (Ritchie et al., 2004; 
Whitehead et al., 2004). In the past years, the early clinical signs of AD have been extensively 
investigated, leading to the concept of amnestic Mild Cognitive Impairment (MCI) (Dubois and 
Albert, 2004; Dubois et al., 2007; Petersen, 2004; Petersen et al., 2001; Winblad et al., 2004). MCI 
patients have cognitive deficits but are capable of independent living. MCI may be symptomatic of 
a transition to early Alzheimer's disease. 
Until recently, the role of neuroimaging in the diagnosis of AD was mainly confined to 
ruling out other causes of dementia. Progress in image acquisition and analysis techniques has 
modified this perspective: the challenge for modern neuroimaging is to help in the diagnosis of 
early AD and particularly in amnestic MCI patients or prodromal AD (Dubois et al., 2007). Three-
dimensional (3D) magnetic resonance imaging (MRI) with high spatial resolution allows 
visualization of subtle anatomical changes and thus can help in the detection of brain atrophy at the 
beginning of the disease. Histopathological studies have shown that the hippocampus is affected by 
neurofibrillary tangles and amyloid plaques in the earliest stages of AD (Braak and Braak, 1995; 
Delacourte et al., 1999). Many studies have thus used MRI to assess in vivo hippocampal atrophy in 
AD, using manual segmentation (Fox et al., 1996; Frisoni et al., 1999; Jack et al., 1992; Jack et al., 
1998; Jack et al., 1997; Juottonen et al., 1999; Killiany et al., 2002; Laakso et al., 1996; Laakso et 
al., 1998; Lehéricy et al., 1994; Seab et al., 1988; Xu et al., 2000). These studies have demonstrated 
that hippocampal volumetry is a valuable marker of AD and can distinguish patients with AD from 
elderly controls with a high degree of accuracy (80% to 90%). However, in patients with MCI, the 
discriminative power of hippocampal volumetry is substantially lower (with reported accuracy 
ranging from 60% to 74%)  (Convit et al., 1997; De Santi et al., 2001; Du et al., 2001; Pennanen et 
al., 2004; Xu et al., 2000). Moreover, manual segmentation of the hippocampus requires a high 
degree of anatomical training, is observer-dependent and time consuming (more than one hour).  
 We previously developed a fully automatic method to segment the hippocampus on MRI 
(Chupin et al., 2009; Chupin et al., 2007). This method has been compared to manual segmentation 
in young healthy participants and patients with AD and has proved to be reliable, fast and accurate 
(about 8% relative volume error when compared to manual segmentation). We have evaluated the 
accuracy of automatic hippocampal volumetry to distinguish between patients with AD, MCI and 
elderly controls and found that it is similar to that of manual volumetry (84% for AD vs controls 
discrimination, 73% for MCI vs controls) (Chupin et al., 2008; Colliot et al., 2008).  
However, volumetric analysis only assesses global changes of the hippocampus. On the 
other hand, shape analysis methods can unveil local atrophy of the hippocampus and may thus be 
more sensitive than volumetry, in particular at the MCI stage. Radial mapping has been used to 
assess local atrophy of the hippocampus in AD and MCI (Apostolova et al., 2006a; Apostolova et 
al., 2006b; Frisoni et al., 2006). In concordance with histopathological studies, marked atrophy was 
found in a region corresponding to the CA1 subfield of the hippocampal formation and the 
subiculum (Frisoni et al., 2006). Other studies relying on the high-dimensional brain mapping 
(HDBM) method (Csernansky et al., 2000; Wang et al., 2006) and a voxel-based approach (Chételat 
et al., 2008)  also found a predominant atrophy in CA1. However, except for (Csernansky et al., 
2000; Wang et al., 2006), these studies were restricted to group analysis and, in their present form, 
most of these methods cannot be used to classify individual patients. Csernansky et al. (2000) used 
the HDBM approach to classify patients with very mild AD and controls. However, they did not 
investigate the classification of MCI patients and it remains unclear whether the diagnostic accuracy 
of this approach is superior to that of volumetry. 
Recently, there has been a growing interest in the use of multidimensional classification 
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methods, such as support vector machines (SVM) (Burges, 1998; Cristianini and Shawe-Taylor, 
2000), to assist in the diagnosis of neurological and psychiatric pathologies (Fan et al., 2008; Fan et 
al., 2007; Kloppel et al., 2008; Lao et al., 2004; Vemuri et al., 2008). In particular, several methods 
have been successfully applied to the classification of patients with AD or MCI. These approaches 
were based on the classification of anatomical features extracted from a set of regions distributed 
across the whole brain. However, these methods did not include a detailed morphological analysis 
of the hippocampus, which is affected at the earliest stages of the pathological process and may thus 
also provide relevant information for the classification of patients.  
In this paper, we introduce a method to automatically discriminate AD and MCI patients 
from healthy controls, based on hippocampal shape features. Shape features are extracted using 
spherical harmonics, a parametric boundary description approach which can be seen as a 3D analog 
of Fourier series (Gerig et al., 2001a; Kelemen et al., 1999; Styner et al., 2004). Spherical 
harmonics coefficients are used as features in a multidimensional classification procedure based on 
support vector machines. 
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Materials and methods 
Participants 
The regional ethics committee approved the study and written informed consent, given by the 
patients themselves, was obtained from all participants. We studied 23 patients with AD (10 males, 
13 females, age ± standard-deviation (SD) = 73 ± 6 years, range = 62–81 years, mini-mental score 
(MMS) = 24.4 ± 2.8, range = 19-29) and 23 patients with amnestic MCI (10 males, 13 females, age 
± SD = 74 ± 8 years, range = 55–87 years, MMS = 27.3 ± 1.4, range = 24-29) recruited at the 
Centre Hospitalo-Universitaire (CHU) of Caen. The diagnosis for probable AD was made according 
to the NINCDS-ADRDA (National Institute of Neurological and Communicative Diseases and 
Stroke-Alzheimer's Disease and Related Disorders Association) criteria (McKhann et al., 1984). 
The diagnosis of MCI was based on Petersen et al.’s criteria (Petersen et al., 2001). All MCI 
patients were evaluated every 6 months over an 18-month period to assess conversion, i.e., whether 
they met NINCDS-ADRDA criteria of probable AD or not. Patients were declared as converters if 
they had impaired performances (more than 1.5 SD below the normal mean according to age and 
education when available) in at least one of general intellectual function scales as well as in at least 
two areas of cognition including memory, leading to impaired daily activities as judged by the 
clinicians from the consultation interviews. Post hoc exclusion criteria included presence of 
substantial neurological, psychiatric or any other medical disease that could affect brain functioning 
or structure, and normal episodic memory performances at follow-up. At completion of the 18-
month follow-up period, seven MCI (7/22=32%) patients were declared as converters, 15 patients 
still had isolated memory deficits (non-converters) and one MCI patient refused follow-up. The 
annual conversion rate was thus 21%. AD and MCI patients were compared to 25 elderly healthy 
controls (13 males, 12 females, age ± SD = 64 ± 8 years, range = 51–84 years) with normal memory 
performance, as assessed using tests of episodic, semantic and working memory, and without 
vascular lesions on MRI. To exclude vascular lesions, all controls were checked to have normal 
signal intensity on T1-, T2- and/or FLAIR-weighted MRI, and notably no substantial white matter 
T2-FLAIR-weighted hyperintensities (less than 5 pinpoint hyperintensities, size <4 mm (Meguro et 
al., 2000)). The controls were screened for the absence of cerebrovascular risk factors, mental 
disorder, substance abuse, head trauma, substantial MRI or biological abnormality, and incipient 
dementia using a memory test battery. Control participants were recruited through advertisement in 
local newspapers. Control participants were required to be over 50 years old. There was no specific 
sex criterion.  
 
MRI acquisition 
Within an interval of two months at most from inclusion for the controls and a few days for MCI 
and AD patients, each participant underwent a T1-weighted volume MRI scan, which consisted of a 
set of 128 adjacent axial slices parallel to the anterior commissure-posterior commissure (AC-PC) 
line and with slice thickness 1.5 mm and pixel size 0.9375x0.9375mm2 using the spoiled gradient 
echo sequence (SPGR) (repetition time (TR)=10.3 ms; echo time (TE)=2.1 ms; field of view 
(FOV)=24*18cm²; matrix=256*192). All the MRI data sets were acquired on the same scanner (1.5 
T Signa Advantage echospeed; General Electric, Milwaukee, WI). 
 
Automatic hippocampal segmentation 
The segmentation of the hippocampus was performed using a fully automatic method we previously 
developed (Chupin et al., 2009; Chupin et al., 2007; Colliot et al., 2008). This approach segments 
both the hippocampus and the amygdala simultaneously based on competitive region-growing 
between these two structures. It includes prior knowledge on the location of the hippocampus and 
the amygdala derived from a probabilistic atlas and on the relative positions of these structures with 
respect to anatomical landmarks which are automatically identified.  
 
SPHARM description 
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Each hippocampus was then described by a series of spherical harmonics, using the SPHARM-
PDM (Spherical Harmonics-Point Distribution Model) software developed by the University of 
North Carolina and the National Alliance for Medical Imaging Computing 
(http://www.namic.org/Wiki/index.php/Algorithm:UNC:Shape_Analysis). SPHARM are a 
mathematical approach to represent surfaces with spherical topology, which can be seen as a 3D 
analog of Fourier series expansion. 
In brief, the SPHARM approach relied on the following steps. Since the automatic 
segmentation is based on homotopic deformations, no topological correction was necessary. 
Hippocampal segmentations were then converted to surface meshes, and a spherical 
parameterization was then computed using the approach proposed in Brechbühler et al. (1995), 
creating a one-to-one mapping between each point on the surface and each point on a sphere. The 
surface Tzyxv )),(),,(),,((),( jqjqjqjq =   was decomposed as: 
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with 0=ijd  if i≠j, and 1=iid  (Kronecker delta) 
The series was then truncated at a given degree (here we empirically chose a degree of L=20 
which results in an acceptable degree of smoothing).  The coefficients of the series expansion were 
normalized in order to eliminate effects of rotation and translation: the parameterization was rotated 
such that the poles of the sphere match with those of the first order ellipsoid (computed from the 
first three SPHARM coefficients). The SPHARM representation was transformed into a 
triangulated surface (called the SPHARM-PDM), based on a uniform subdivision of the spherical 
parameterization. Each hippocampus was described by a set of 4002 landmarks. The SPHARM-
PDM were finally spatially aligned using rigid Procustes alignment. To that purpose, we created a 
template by averaging all hippocampal surfaces. Specifically, for each of the 4002 landmarks, we 
computed the arithmetical mean over the whole population. This resulted in an average 
hippocampal surface formed by the 4002 mean landmarks. Each individual hippocampus was then 
aligned with respect to that average template. A new template was then formed by averaging the 
aligned surfaces using the procedure described above. This process was iterated until convergence 
of the template (i.e. when the template was no longer modified). This alignment resulted in a one-
to-one mapping between points of each hippocampus. The corresponding rigid-body transform was 
then applied to the SPHARM decomposition, resulting in a new set of SPHARM coefficients. 
We obtained two types of correspondences between objects:  
• SPHARM coefficients, which were entered as features in the SVM classification; 
• SPHARM-PDM landmarks, which were used to visualize the localization of shape 
differences between groups (Styner et al., 2004). 
 
Feature Extraction and Selection 
The classification features were based on the SPHARM coefficients. Specifically, each subject was 
represented by two sets (one for each hippocampus) of three-dimensional SPHARM coefficients 
m
lc . When considering a SPHARM decomposition up to degree 20, each subject can thus be 
represented by a feature vector of size 2646 which is obtained by concatenating the three 
7 
coordinates of all coefficients for both sides. Indeed, decomposition up to degree 20 results in 
(20+1)2 vector coefficients. Moreover, there are 2 hippocampi and 3 spatial coordinates. There are 
thus 2x3x(20+1)2 =2646 features. In the following, the vector corresponding to the k-th subject is 
denoted as: nkn
kk xxx ÂÎ= ),...,( 1  where n=2646 is the number of features.  
Among these features, only some of them convey relevant information for the classification of 
patients. To identify the most discriminative features for the SVM classification, we used a 
univariate feature selection combined with a bagging strategy.  We used Student's t-tests in order to 
determine which features best separate the different populations. In order to obtain a robust 
selection, the T statistics were computed using a bagging approach (Breiman, 1996; Fan et al., 
2007). This approach proceeds as follows:  
For the i-th feature, we computed the iT  statistics as follows  
• For the k-th subject , we computed the  iT statistics from the set { }kk xXX -=)(   
• In order to keep only those features which are always significantly different, we 
computed )(min kiki TT =  
We repeated this procedure for each of the initial features, and sorted them by increasing iT . The p 
features which result in the highest iT  values were kept as features in the SVM. The selected 
features were then centered and normalized using a z-score. In the following, in order to simplify 
notations, we denote the vector of selected, normalized, sorted, and centered features as 
.),,( 1
pk
p
kk xxx ÂÎ= !  
 
Classification using SVM 
A support vector machine is a supervised learning method. In brief: given a training set 
{ } Kkkk yx !1, = , where pkx ÂÎ   are observations, and { }1,1-Îky  are corresponding labels (-1 for 
controls, 1 for patients for example), linear SVMs search for the optimal hyperplane separating 
groups, i.e. the hyperplane for which the margin between groups is maximal. To that purpose, the 
following constrained optimization problem is solved:  
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where C is a cost parameter and the ξk are positive slack variables allowing some examples to lie on 
the wrong side of the soft margin. Let the classification function be: ).(sign)( bwxxf +=  where w 
determines the orientation of the hyperplane, and b the offset from the origin. The vector w 
maximizing the margin can be written as a linear combination of some training examples, called 
support vectors. The classification function depends only on dot products of the data. SVM can be 
used to construct nonlinear separations by replacing the dot product with a kernel evaluation into 
the original problem. Here, we chose to use Radial Basis Functions kernels (RBF): 
2
),( vuevuK --= gg , where the parameter γ controls the width of the kernel. We also compared the 
performance of the RBF kernel with that of a linear kernel. The SVM implementation relied on the 
LIBSVM Library (http://www.csie.ntu.edu.tw/~cijlin/libsvm). More details on SVM can be found 
in Cristianini and Shawe-Taylor  (2000). 
 
Validation 
Classification accuracy (proportion of subjects correctly classified among the whole population), 
error (proportion of subjects wrongly classified), sensitivity (proportion of AD or MCI patients 
correctly classified) and specificity (proportion of healthy controls correctly classified) were 
computed using leave-one-out cross validation. To avoid introducing bias in the feature selection, 
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the feature selection step detailed above was integrated in the leave-one-out procedure. In this 
procedure, each subject was successively selected as the test subject and all remaining subjects were 
used for the feature selection and classifier training. To estimate the optimal parameters C and γ of 
the SVM, we used a grid search with values ranging from C=20… 220 and γ=2-15… 20. We 
computed the classification accuracy for different number of selected features (corresponding to 
different thresholds on the p-value of the T statistic). 
 
Comparison with a voxel-based SVM approach 
We compared our approach to that proposed by Klöppel et al. (2008) in the same context of 
automatic classification of patients with AD. Klöppel et al. (2008) propose two different versions of 
their approach: one is based on whole-brain data and the other includes only data from a region of 
interest (ROI) located in the anterior medial temporal lobe, including part of the hippocampus. This 
allows comparing the accuracy of our approach to both a whole-brain approach and an approach 
restricted to the hippocampal region. In brief, the approach of Klöppel et al. (2008) relied on the 
following steps. Images were first segmented into gray matter (GM), white matter and cerebrospinal 
fluid using SPM5 (Statistical Parametric Mapping, Institute of Neurology, University College 
London, London, UK). Then, GM segmentations were further normalized to the population 
templates generated from all the images involved in each classification experiment (i.e. all AD and 
control subjects for the AD vs controls classification experiment, all MCI and controls for MCI vs 
controls classification), using the DARTEL diffeomorphic registration algorithm (Ashburner et al., 
2007). Tissue classes were then modulated to ensure that the overall amount remained constant. No 
spatial smoothing was performed. Kernel matrices were then created from normalized GM 
segmented images and used to classify patients using linear and RBF SVM. The classification was 
then performed using the two different types of analysis: the first one using whole-brain data and 
the second one using data from a hippocampus-centered ROI. Leave-one-out accuracies were 
optimized with respect to C and γ with the same range of parameters as in our method.  
 In our method, we selected the optimal number of features based on multiple leave-one-out 
experiments. This can introduce a bias in the evaluation. No such bias is present in Klöppel et al’s 
method. In order to fairly compare these two approaches, we need to evaluate our method without 
the bias concerning the number of selected features. We therefore tested both approaches on a 
completely separate group, while computing the threshold on the p-value for feature selection on 
the original group. To that purpose, we randomly selected from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu/ADNI) 25 AD patients (age: 75 ± 6 
years, MMS=23.3±2), 25 patients with amnestic MCI (age: 75 ± 5 years, MMS= 26.6±1.8), and 26 
elderly cognitively normal individuals (age: 75 ± 4 years, MMS=28.9±1.3). The ADNI was 
launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical 
Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private 
pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public-private 
partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging 
(MRI), positron emission tomography (PET), other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of mild cognitive 
impairment (MCI) and early Alzheimer’s disease (AD). Determination of sensitive and specific 
markers of very early AD progression is intended to aid researchers and clinicians to develop new 
treatments and monitor their effectiveness, as well as lessen the time and cost of clinical trials. The 
Principal Investigator of this initiative is Michael W. Weiner, M.D., VA Medical Center and 
University of California - San Francisco. ADNI is the result of efforts of many co-investigators 
from a broad range of academic institutions and private corporations, and subjects have been 
recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 
adults, ages 55 to 90, to participate in the research – approximately 200 cognitively normal older 
individuals to be followed for 3 years, 400 people with MCI to be followed for 3 years, and 200 
people with early AD to be followed for 2 years. For up-to-date information see www.adni-info.org. 
 The complete classification procedure was the same as before, apart from feature selection. 
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For feature selection, instead of optimizing the number of features, we used the optimal p-value 
computed for the original group (p=0.002) and applied it directly to the ADNI group. There is no 
bias in this selection since no data from the ADNI group was used to compute the p-value threshold. 
We also tested the performance obtained on the original group when the optimal p-value is 
computed on the ADNI group. 
 
Comparison with classification approaches based on SPHARM-PDM  
We compared the accuracy of classification based on SPHARM to that of classification based on 
the SPHARM-PDM. To that purpose, we performed two experiments. In the first experiment, we 
applied to the SPHARM-PDM the same univariate feature selection strategy that we used in our 
method for the SPHARM coefficients. We computed the classification accuracies obtained with a 
SVM, for varying numbers of features. In the second experiment, the dimensionality of the 
SPHARM-PDM was reduced using principal component analysis (PCA). The resulting 
eigenvectors were ranked by decreasing order according to their corresponding eigenvalues. We 
computed the classification accuracies obtained with a SVM, for varying numbers of eigenvectors.  
 We also compared our approach to that proposed by Shen et al. (2003a). This approach 
relied on the following steps: each hippocampus was described by a set of SPHARM-PDM 
landmarks (the number of landmarks was 642 as described in (Shen et al., 2003a)). The 
dimensionality of the SPHARM-PDM was reduced using PCA. The eigenvectors were ranked in 
decreasing order. Fisher’s Linear Discriminant (FLD) was used as a classifier. This is quite similar 
to the experiment performed above except that it relies on FLD instead of SVM. As indicated in 
(Shen et al., 2003a), two experiments (one for the left hippocampi, the other for the right) were 
performed, and classification was computed while letting the number of principal components (PC) 
vary. 
 
Statistical group analysis using SPHARM-PDM 
In order to illustrate the behaviour of the SPHARM approach for the detection of local hippocampal 
abnormalities, we used the SPHARM-PDM to perform a statistical group analysis investigating the 
differences between AD/MCI patients and healthy controls. It should be noted that this analysis is 
presented here only for illustrative purposes, in order to compare the behaviour of SPHARM with 
other hippocampal morphometric studies in AD, and that the SPHARM-PDM were not used for the 
classification of subjects.  
To test for group differences in the spatial location (x,y,z) at each vertex of the hippocampal 
surface, we used the multivariate Hotelling T² metric (Styner et al., 2006). For each group, the mean 
iµ  and the covariance matrix iS  of the spatial location were computed. Then the modified T² metric 
at each vertex was given by: 
)()11()( 21
1
2
2
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1
21
2 µµµµ -S+S-= -
KK
T T  
where iK  is the number of subjects of the i-th group. 
P-values were obtained via permutation tests. This analysis was repeated at each vertex, resulting in 
a significance map, which shows local group differences. The p-values were corrected for multiple 
comparisons using a permutation-based approach (Styner et al., 2006).  
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Results 
Classification results  
The classification accuracy for a varying number of features is shown on Figures 1 and 2. For AD 
vs controls classification, the best classification was obtained for a number of features between 16 
and 22 (which corresponds to a p-value of 0.002), giving a correct classification rate of 94%, a 
sensitivity of 96%, and a specificity of 92%. For MCI vs controls, the best classification was 
obtained for a number of features between 2 and 3 (which also corresponds to a p-value of 0.002), 
giving a correct classification rate of 83%, a sensitivity of 83%, and a specificity of 84%. The 
accuracy of the RBF classifier was always superior (or equal) to that of the linear classifier. Figures 
3 and 4 show the classification accuracy for different values of the parameters C and γ, for an 
optimal number of features (i.e. 19 for AD, 3 for MCI). There is a substantially large set of values 
which lead to optimal accuracy.  
To assess the influence of the degree of decomposition on the classification performance, we 
repeated the selection and classification procedure with different values of maximal degree L (L=5, 
L=10, L=15, L=20). For AD vs controls classification, the accuracy was 92% for L=5 and L=10, 
and 94% for L=15 and L=20. For MCI vs controls classification, the accuracy was 83% for L=5, 
10, 15 and 20.   
SPHARM coefficients cannot be used directly to visualize the localization of shape changes 
because SPHARM basis functions have a global support across the sphere. Thus, coefficients are 
not associated to a localized area, but rather to a mode of deformation. To illustrate the influence of 
discriminative coefficients on hippocampal shape, we created a mean shape by averaging all 
coefficients across the AD and controls group. We chose the two most discriminative coefficients 
for the AD vs controls separation. We then illustrated the modes of variation by adding or 
subtracting 2SD of these two most discriminative coefficients (Figure 5). 
 
 
Comparison with a voxel-based SVM approach 
The comparison between our approach and the one proposed by Klöppel et al. (2008) is presented 
in Table 1. On the ADNI group, our method reached 88% accuracy, 84% sensitivity and 92% 
specificity for AD vs controls and 80% accuracy, 80% sensitivity and 80% specificity for MCI vs 
controls. For AD vs controls classification, the accuracy reached by Klöppel’s method (90%) was 
similar to that of our approach. For MCI vs controls, the accuracy was 71% which is substantially 
lower than our results. 
 When the optimal p-value was computed on the ADNI group and applied to the original 
group, our method reached 88% accuracy, 91% sensitivity and 84% specificity for AD vs controls 
and 79% accuracy, 78% sensitivity and 80% specificity for MCI vs controls. Thus, the results 
obtained when selecting the p-value on the ADNI group or on the original group are very similar. 
 
Comparison with classification approaches based on SPHARM-PDM  
Using the SPHARM-PDM, univariate feature selection and SVM classification, we obtained the 
following results. AD vs controls classification reached 92% which is similar to our approach. For 
MCI vs controls, the accuracy reached 75% which is substantially lower than that obtained with our 
approach based on SPHARM coefficients (83%). Using the SPHARM-PDM, PCA and SVM 
classification, we obtained the following results. For AD vs controls, the best result was obtained 
for 15 eigenvectors, giving a correct classification rate of 94% which is the same as for the 
SPHARM coefficients. For MCI vs controls, the best result was obtained for five features, giving a 
correct classification rate of 69% which is substantially lower than with our approach.  
For AD vs controls, the method proposed by Shen et al., (2003a) achieved 92% accuracy for 
the left hippocampi (using between 9 and 11 PC) and 96% for the right hippocampi (using 24 PC). 
For MCI vs controls, accuracy was 67% for the left hippocampi (with 11 PC) and 73% for the right 
hippocampi (8 PC), which is lower than with our approach. 
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 Therefore, using SPHARM coefficients seems more efficient than using the PDM to 
discriminate between MCI patients and controls. 
 
Statistical group analysis using SPHARM-PDM 
The maps of group differences between AD/MCI patients and controls are shown in Figures 6 and 
7. For the AD vs controls comparison, the most significant deformations are shown in the medial 
part of the head of the hippocampus, and in a region approximately corresponding to CA1 subfield. 
CA2 and CA3 regions are relatively spared. Similar but less extended patterns are found for the 
MCI vs controls comparison.  
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Discussion 
In this paper, we proposed a new approach to automatically discriminate patients with Alzheimer’s 
disease and MCI from normal aging, based on multidimensional classification of hippocampal 
shape features. The SVM-based classification resulted in a high degree of accuracy. 
Hippocampal shape features were extracted by expanding hippocampal surfaces into series 
of spherical harmonics (SPHARM). SPHARM have been applied to study morphological 
abnormalities of brain structures in several pathologies. However, it has been mainly used to assess 
group differences (Gerig et al., 2001a; Shi et al., 2007; Styner et al., 2004) rather than to assist 
individual diagnosis. Gerig et al. (2001b) individually classified patients with schizophrenia using 
the mean square distance (MSD) derived from SPHARM. However, using the MSD leads to a 
univariate classification in which the relationships between coefficients are not taken into account. 
Shen et al. (2003b) used the SPHARM-PDM landmarks as features to classify patients with 
schizophrenia. Here, we relied on SPHARM coefficients (and not on the SPHARM-PDM) to 
extract features which were used in a multidimensional SVM-based classification method. These 
coefficients are well suited to building classification features because they provide a multi-scale 
representation and thus the different features correspond to different levels of detail. In particular, 
the first features concentrate a lot of geometrical information. This property may be related to the 
fact that a relatively small number of features was sufficient to discriminate between subjects. On 
the other hand, it is likely that each isolated SPHARM-PDM landmark does not convey a lot of 
information and that a larger number of features would be necessary for the discrimination. To 
robustly select relevant features among the whole set of coefficients, we used a bagging strategy 
and leave-one-out cross-validation was performed to evaluate accuracy.  
Our approach achieved classification accuracies of 94% for AD vs controls, 83% for MCI vs 
controls. These rates are higher to that reported for manual hippocampal volumetry in various 
studies, in particular for the MCI patients. Indeed, while manual hippocampal volumetry can 
discriminate AD patients from controls with a high degree of accuracy, ranging from 82% to 90% 
(Frisoni et al., 1999; Jack et al., 1992; Laakso et al., 1998; Lehéricy et al., 1994; Xu et al., 2000), 
the accuracy obtained for MCI patients is usually much lower, ranging from 60% to 74% (Convit et 
al., 1997; De Santi et al., 2001; Du et al., 2001; Pennanen et al., 2004; Xu et al., 2000). Thus, taking 
into account shape deformations seems to result in a higher discriminative power than considering 
only volume, which is a global marker of atrophy. Moreover, most volumetric studies previously 
relied on manual segmentation, which is time-consuming and requires specific training and is thus 
not suitable to clinical practice. To overcome this difficulty, we segmented the hippocampi with 
recently developed fully automatic software. Thus, the procedure presented in this paper, from 
hippocampal segmentation to classification, is fully automatic and does not require user 
intervention. 
The optimal classification was obtained for a number of features comprised between 16 and 
22 for AD patients and between 2 and 3 for MCI patients. Interestingly, these numbers of features 
correspond to approximately the same statistical threshold (p=0.002). This implies that, at a given 
statistical threshold, there are more discriminative features for AD patients than for MCI patients, 
which reflects the fact that atrophy is greater in AD than MCI. Thus, there are more useful features 
for the SVM in the case of AD patients than for MCI. When irrelevant features are added, the 
performance of the classifier drops. Besides, the accuracy of the RBF classifier was always superior 
(or equal) to that of the linear SVM. This suggests that the best separation of our data is nonlinear. 
Moreover, the fact that the RBF was always at least as good as the linear SVM may be related to the 
asymptotic behaviour of RBF. Indeed, as shown by Keerthi and Lin (2003), when γ is close to zero 
and C=Ĉ/2γ where Ĉ is fixed, then the RBF classifier converges to a linear SVM with penalty 
parameter Ĉ. As a result, when a complete search for parameters γ and C has been performed 
(which was the case in our study), the RBF classifier is at least as accurate as the linear SVM 
(Keerthi and Lin, 2003). Furthermore, there is a substantially large range of optimal values for 
parameters C and γ of the SVM. This suggests that the approach is relatively robust to the choice of 
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these parameters. However, leave-one-out cross-validation accuracies can be optimistic, since the 
search for optimal parameters, as well as the selection of the number of features, occurred outside of 
the leave-one-out loop. As a consequence, the information about each left-out subject could help in 
the selection of optimal parameters C and γ, and the number of features. To be fully representative 
of the generalization performance, the accuracy should be computed using a three-way split. 
However, the relatively small sample size in our study forbids us from conducting a three-way split 
procedure. This is also the case in Fan et al. (2007) which reports leave-one-out accuracies. On the 
contrary, in Vemuri et al. (2008), the test data was completely isolated from the data that was used 
for parameter selection. 
The accuracy was not heavily influenced by the degree of the SPHARM decomposition. For 
AD vs controls, the results were identical for degrees 15 and 20 and very similar for degrees 5 and 
10. For MCI vs controls, the results were the same for degrees 5, 10, 15 and 20. Indeed, the selected 
coefficients had a degree inferior or equal to 4. Nevertheless, even if for MCI lower degrees led to a 
good accuracy, it still seems preferable to use a decomposition of a relatively high degree (probably 
around 15) in order to ensure an accurate registration of shapes. 
Although lesions start in the medial temporal lobe, atrophy is also present in a distributed 
pattern of brain regions, including the temporal neocortex, the cingulate gyrus, the precuneus, the 
temporo-parietal association and the perisylvian association (Baron et al., 2001; Chételat et al., 
2002; Chételat et al., 2005; Karas et al., 2003; Karas et al., 2004; Lerch et al., 2005) . Several 
authors have thus recently proposed to classify patients based on whole brain data and not only 
from a single structure (Fan et al., 2008; Kloppel et al., 2008; Vemuri et al., 2008). In these 
approaches, the SVM uses structural features which are extracted from a set of anatomical regions 
distributed across the brain. The reported classification accuracies range from 89% to 96% (Fan et 
al., 2008; Kloppel et al., 2008; Vemuri et al., 2008) for AD vs controls discrimination, and from 
82% to 90% for MCI vs controls (Davatzikos et al., 2008a; Fan et al., 2008). Using a different 
strategy in which SVM features are formed from the hippocampus only, we achieved similar 
classification rates (94% for AD patients, 83% for MCI patients). Our approach, based on a detailed 
shape analysis but restricted to a single structure, and these whole brain methods, which use 
extensive but less detailed information, seem complementary. Ultimately, it seems interesting to 
combine these approaches in an integrated classification method. The AD cases included in our 
study were less severely affected (mean MMS=24) than those studied in Kloppel et al. (2008) 
(mean MMS=17) and in Vemuri et al. (2008) (median MMS=20). It should be noted that the 
patients studied by Kloppel et al. (2008) were pathologically confirmed. The disease severity of our 
AD and MCI patients was similar to those included in Fan et al. (2008) (mean MMS=23 for AD and 
27 for MCI) and in Davatzikos et al. (2008a) (mean MMS=26 for MCI).  
We compared our approach to that proposed by Klöppel et al. (2008). Klöppel et al. (2008) 
propose two different versions of their approach: one is based on whole-brain data and the other 
includes only data from a region of interest (ROI) located in the anterior medial temporal lobe, 
including part of the hippocampus. In order to perform a fair comparison between our approach and 
theirs, we determined the optimal threshold for feature selection on the original group of subjects 
and used a completely separated group for the evaluation. For MCI vs controls classification, the 
accuracies obtained with their method were lower than with our approach (63% for whole-brain, 
71% for hippocampal ROI, compared to 80% for our method). For AD vs controls, the accuracy of 
their whole-brain method increased to 90%, which is slightly superior to our results (88%). This 
comparison experiment should be confirmed in larger groups of patients. However, these results 
indicate that a specific analysis of hippocampal shape may be more sensitive than an approach 
using a ROI, defined at the group level, to discriminate MCI patients from controls. Indeed, using a 
specific segmentation method dedicated to the hippocampus allows precisely defining the 
boundaries of this structure in each individual subject. On the contrary, Klöppel et al. (2008) use a 
region of interest defined at the group level which also encompasses other structures. Nevertheless, 
whole-brain methods, such as the one proposed by Klöppel et al. (2008), are likely to be more 
efficient to discriminate between different types of dementia. In particular, Klöppel et al. (2008) and 
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Davatzikos et al. (2008b) successfully applied whole-brain approaches to the differentiation of 
patients with AD and FTLD (fronto-temporal lobar degeneration).  
 We also compared our approach based on SPHARM coefficients to classifications based on 
SPHARM-PDM. First, we compared our approach to a classification based on SVM and SPHARM-
PDM. Second, we performed a comparison with the approach of Shen et al., (2003a) which uses a 
FLD classifier. In both cases, our approach reached a higher accuracy for MCI vs controls 
classification. This suggests that using the coefficients is more efficient than using the PDM to 
discriminate between MCI patients and controls. 
Although ADNI MCI patients are slightly more impaired than ours (mean MMSE= 26.6 vs 
27.3, respectively), this difference was not statistically significant (p=0.13), and the classification 
results obtained on our data were very close to those obtained on ADNI data. 
Most studies of hippocampal shape in AD were restricted to group analysis and not to the 
discrimination of individual patients (Apostolova et al., 2006a; Apostolova et al., 2006b; Chételat et 
al., 2008; Csernansky et al., 2000; Frisoni et al., 2006; Shen et al., 2005; Wang et al., 2006) with the 
exception of Csernansky et al. (2000) in which the high-dimensional brain mapping (HDBM) 
approach was used to obtain hippocampal volumes and hippocampal shape differences between 
patients with very mild AD and controls. Using a classification based on both volume and shape 
features, they achieved a sensitivity of 83% and a specificity of 78%, which is lower than those 
obtained in our study. Moreover, they did not investigate the discrimination of MCI patients from 
controls. Another exception is Li et al., (2007) who proposed a method for shape analysis of the 
hippocampus based on SVM. An important difference between their approach and ours is that their 
features represent the average deformation of a surface patch from a mean surface. For AD vs 
controls classification, their reported accuracies are similar to ours (between 84% and 94%). 
However, it should be noted that the AD patients included in their study are at a more severe stage 
than ours (MMS=19 vs 24). Moreover, they did not investigate the classification of MCI patients. 
Using SPHARM-PDM, we studied the localization of hippocampal shape changes between 
AD or MCI patients and controls. We found that AD patients exhibit a spatial pattern of 
deformations that approximately corresponds to the CA1 subfield of the hippocampus. CA2 and 
CA3 are relatively spared. In MCI patients, a similar but less extended spatial pattern was found. 
Although our method cannot provide a direct mapping of hippocampal subfields since these are 
below the resolution of conventional MRI, this is in concordance with histopathological studies 
which demonstrated that neurofibrillary tangles and neuronal loss predominate in the CA1 subfield 
(Hyman et al., 1984; Van Hoesen and Hyman, 1990). Previous hippocampal morphometric studies 
in AD have relied on different types of methodologies: the high-dimensional brain mapping 
(HDBM) approach (Csernansky et al., 2000; Wang et al., 2006), radial mapping (Apostolova et al., 
2006b; Frisoni et al., 2006) and a voxel-based method  (Chételat et al., 2008). Their main finding is 
that atrophy is predominant in the CA1 region.  
 The results of our study require confirmation in larger groups of participants. However, the 
use of a bagging strategy brings robustness to the feature selection. Nevertheless, the relatively 
small size of the samples may explain why the classification accuracy diminishes when less 
relevant features are added, in particular for MCI patients. In order to keep the control group as 
large as possible, we decided not to exclude control participants based on age. As a consequence, 
the mean age of the controls was significantly lower (p<0.001) than those of the AD and MCI 
patients. However, it should be noted that misclassified controls were not always among the oldest.  
The misclassified controls were respectively 53 and 84 years old for AD vs controls classification, 
and 59, 67, 70 and 84 years for MCI vs controls classification. Nevertheless, further studies on 
larger age-matched groups of participants are required to confirm our results. Moreover, we could 
not investigate the classification of converters vs non-converters, due to the small number of 
converters. Indeed, MCI is a heterogeneous population and not all MCI patients have prodromal 
AD. Further studies on larger groups of longitudinally followed MCI patients are needed to assess 
whether our method can identify patients with incipient AD in an MCI population. 
Using multidimensional classification of hippocampal shape features, we were able to 
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individually classify Alzheimer's disease, MCI and control participants with a high degree of 
accuracy. This method may become a useful tool to assist in the diagnosis of Alzheimer’s disease. 
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Tables 
 
Table 1. Comparison between our approach and the method proposed by Klöppel et al., (2008), on 
the ADNI group.  
 
  
Our method Klöppel’s whole brain Klöppel’s ROI 
Linear 
kernel RBF kernel 
Linear 
kernel RBF kernel 
Linear 
kernel RBF kernel 
AD vs. 
Controls 86% 88% 90% 90% 84% 86% 
MCI vs. 
Controls 78% 80% 63% 63% 71% 71% 
  
 
21 
Figures 
 
Figure 1. AD vs controls classification. The classification accuracy is shown as a function of the 
number of selected features. Using a SVM with a RBF kernel gives the highest accuracy (94%), for 
a number of features between 16 and 22.  
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Figure 2. MCI vs controls classification. The classification accuracy is shown as a function of the 
number of features. Using a SVM with a RBF kernel gives the highest accuracy (83%), with a 
number of features between 2 and 3. 
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Figure 3. Classification rates for AD vs controls, as a function of the parameters C and γ. The 
following results are shown: accuracy, error, sensitivity and specificity. A “grid-search” approach 
was conducted in order to select the best parameters. The cost parameter C ranges from 20 to 220. 
The parameter γ, corresponding to the width of the RBF kernel, ranges from n 2-15 to 20. Results are 
displayed for the classifier with 19 features, for which the best performance is obtained. 
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Figure 4. Classification rates for MCI vs controls, as a function of the parameters C and γ. The 
following results are shown: accuracy, error, sensitivity and specificity. A “grid-search” approach 
was conducted in order to select the best parameters. Results are displayed for a classifier with 3 
features, for which the best performance is obtained. 
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Figure 5. Illustration of the influence of the two most discriminative SPHARM coefficients on 
hippocampal shape for AD vs controls classification. A mean shape was created by averaging all 
coefficients across the AD and controls group. To illustrate the modes of variation, we added or 
subtracted to the mean shape 1SD or 2SD of the two discriminative coefficients.  
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Figure 6. Group differences between AD and controls. Regions with statistically significant 
atrophy (p<0.05) are displayed in colors ranging from yellow to red, blue areas correspond to 
regions with no significant differences. P-values are corrected for multiple comparisons. The medial 
aspect of the head and the lateral aspect of the body, approximately corresponding to the CA1 
subfield, are affected by deformations in AD patients. 
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Figure 7. Group differences between MCI and controls. Regions with statistically significant 
atrophy (p<0.05) are displayed in colors ranging from yellow to red, blue areas correspond to 
regions with no significant differences. P-values are corrected for multiple comparisons. The 
patterns of atrophy are similar to those of the AD vs controls comparison but with a smaller spatial 
extent. 
 
 
 
  
 
